other material
confidence high
sentiment positive
materiality 0.80
Skye Bioscience reports 52-week weight loss of 22.3% for nimacimab+semaglutide combo; no plateau observed
Skye Bioscience, Inc.
- Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.
- Weight regain at 13-week off-therapy follow-up was 17.8% for combo vs 37.3% for semaglutide alone, a >50% reduction in rebound.
- No serious adverse events or AESIs reported during 52-week extension; safety profile maintained.
- Full topline Phase 2a extension data expected in Q3 2026; cash runway into Q4 2026.